RCEL Avita Medical, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026RCEL Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
RCEL Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| June 30, 2020 | 1-for-5 | Reverse |
About Avita Medical, Inc. - Common Stock Company overview from Wikipedia
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage (temporization) after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the NASDAQ Capital Market under the ticker symbol RCEL.
ReCell, spray-on skin
ReCell is a device that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells. The procedure is performed on site at bedside and takes approximately 25 minutes to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in the United States, Europe, the United Kingdom, Australia, New Zealand, Japan and China.
February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption (IDE) program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment.
In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority (BARDA) to raise money toward commercializing the product on the U.S. market.
September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries.
September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval (PMA), and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program.
On September 20, 2018, Avita Medical's ReCell wound care device received FDA PMA approval.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | RCEL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -8.95Y avg ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.25Y avg ≈4.6 | ≈4.6 | 44.3 | Undervalued | |
| P/B (MRQ) | -14.15Y avg ≈19.4 | ≈19.4 | · | · | |
| EV / EBITDA (TTM) | -13.15Y avg ≈-5.6 | ≈-5.6 | · | · | |
| Price / FCF (TTM) | -16.05Y avg ≈-6.6 | ≈-6.6 | · | · | |
| Price / Cash Flow (TTM) | -16.25Y avg ≈-7.1 | ≈-7.1 | · | · | |
| EV / Revenue (TTM) | 5.75Y avg ≈4.4 | ≈4.4 | · | · | |
| EV / FCF (TTM) | -17.45Y avg ≈-5.9 | ≈-5.9 | · | · | |
| Price / Tangible Book (MRQ) | -11.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | RCEL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 81.6%5Y avg ≈83.7% | ≈83.7% | · | · | |
| Operating Margin (TTM) | -46.6%5Y avg ≈-78.1% | ≈-78.1% | -283.6% | Top tier | |
| EBITDA Margin (TTM) | -43.3%5Y avg ≈-76.1% | ≈-76.1% | -281.6% | Top tier | |
| Pretax Margin (TTM) | -56.9%5Y avg ≈-77.9% | ≈-77.9% | -286.2% | Top tier | |
| Net Profit Margin (TTM) | -57.0%5Y avg ≈-78.0% | ≈-78.0% | -337.7% | Top tier | |
| ROA (TTM) | -81.4%5Y avg ≈-48.7% | ≈-48.7% | -43.7% | Weak | |
| ROE (TTM) | 211.5%5Y avg ≈-126.2% | ≈-126.2% | -37.3% | Top tier | |
| ROIC | -161.5%5Y avg ≈-90.8% | ≈-90.8% | -70.9% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | RCEL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -1.75Y avg ≈2.5 | ≈2.5 | · | · | |
| Current Ratio (MRQ) | 0.45Y avg ≈4.9 | ≈4.9 | 5.3 | Low liquidity | |
| Quick Ratio (MRQ) | 0.35Y avg ≈4.5 | ≈4.5 | 2.5 | Low liquidity | |
| Long-Term Debt / Equity | 0.05Y avg ≈3.4 | ≈3.4 | · | · | |
| Interest Coverage | -8.55Y avg ≈-443.9 | ≈-443.9 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | RCEL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 11.5%5Y avg ≈28.4% | ≈28.4% | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | RCEL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 1.15Y avg ≈0.6 | ≈0.6 | 0.0 | Top tier | |
| Inventory Turnover | 1.85Y avg ≈2.0 | ≈2.0 | · | · | |
| Receivables Turnover | 6.95Y avg ≈8.2 | ≈8.2 | · | · | |
| Revenue / Employee | ≈$316.9K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-0.25 | $-0.29 | 14.5% |
| March 31, 2026 | May 14, 2026 | $-0.35 | $-0.29 | -22.5% |
| Dec. 31, 2025 | $-0.38 | $-0.34 | -10.9% | |
| Sept. 30, 2025 | $-0.46 | $-0.29 | -58.8% | |
| June 30, 2025 | $-0.38 | $-0.25 | -50.2% | |
| March 31, 2025 | $-0.53 | $-0.39 | -35.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · | $14M | $5M | |
| Cost of Revenue | $13M | $9M | $8M | $6M | · | $3M | $1M | |
| Gross Profit | $59M | $55M | $42M | $28M | · | $11M | $4M | |
| R&D Expense | $21M | $20M | $21M | $14M | · | $9M | $8M | |
| SG&A Expense | $27M | $33M | $28M | $23M | · | $33M | $15M | |
| Operating Expenses | $101M | $112M | $86M | $59M | · | $58M | $36M | |
| Operating Income | $-43M | $-57M | $-43M | $-28M | · | $-43M | $-26M | |
| Interest Expense | $5M | $5M | $1M | $16.0K | · | $33.0K | $27.0K | |
| Other Non-op | $-1M | $163.0K | $8M | $892.0K | · | · | · | |
| Pretax Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| Income Tax | $11.0K | $54.0K | $66.0K | $36.0K | · | $4.0K | $-121.0K | |
| Net Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| EPS (Basic) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| EPS (Diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| Shares (Basic) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| Shares (Diluted) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| EBITDA | $-40M | $-55M | $-42M | $-27M | · | · | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $14M | $22M | $18M | $56M | $74M | $20M | |
| Short-term Investments | $8M | $22M | $67M | $61M | $30M | · | · | |
| Receivables | $9M | $12M | $8M | $4M | $3M | $2M | $1M | |
| Inventory | $7M | $7M | $6M | $2M | $2M | $1M | $742.0K | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $990.0K | $1M | |
| Other Current Assets | · | · | $18.0K | $127.0K | $15.0K | $75.0K | $125.0K | |
| Current Assets | $35M | $57M | $104M | $87M | $92M | $78M | $24M | |
| PP&E (Net) | $9M | $10M | $2M | $1M | $1M | $1M | $1M | |
| Accum. Depreciation | $5M | $3M | $2M | $2M | $2M | $881.0K | $667.0K | |
| Intangibles | $6M | $6M | $487.0K | $465.0K | $443.0K | $364.0K | $225.0K | |
| Other Non-current Assets | $612.0K | $546.0K | $355.0K | $122.0K | $638.0K | $1.0K | $125.0K | |
| Total Assets | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Accounts Payable | $9M | $6M | $4M | $3M | $3M | $4M | $2M | |
| Current Liabilities | $63M | $20M | $13M | $11M | $9M | $8M | $4M | |
| Capital Leases | $2M | $3M | $2M | $306.0K | $918.0K | $2M | · | |
| Other Non-current Liabilities | · | · | · | · | $113.0K | $0 | $42.0K | |
| Total Liabilities | $73M | $75M | $62M | $13M | $11M | $10M | $5M | |
| Long-term Debt | $43M | $42M | · | · | · | · | · | |
| Total Debt | $43M | $42M | $40M | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $394M | $368M | $350M | $340M | $332M | $259M | $165M | |
| Retained Earnings | $-408M | $-360M | $-298M | $-263M | $-236M | $-195M | $-153M | |
| AOCI | $-1M | $-2M | $-2M | $8M | $8M | $8M | $8M | |
| Stockholders' Equity | $-17M | $4M | $49M | $85M | $105M | $72M | $21M | |
| Liabilities + Equity | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Shares Outstanding | 30,571,662 | 26,354,042 | 25,682,078 | 25,208,436 | 24,925,743 | 21,467,912 | 18,712,996 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $1M | $632.0K | $568.0K | · | $465.0K | $269.0K | |
| Stock-based Comp | $10M | $13M | $8M | $7M | · | $16M | $2M | |
| Amort. of Intangibles | $600.0K | $93.0K | $35.0K | $58.0K | · | $119.0K | $0 | |
| Other Non-cash | $6M | $-2M | $-12M | $9.0K | · | · | · | |
| Operating Cash Flow | $-31M | $-49M | $-38M | $-19M | · | $-23M | $-19M | |
| CapEx | $1M | $9M | $1M | $452.0K | · | $590.0K | $1M | |
| Investing Cash Flow | $12M | $37M | $2M | $-19M | · | $-847.0K | $-1M | |
| Debt Issued | · | · | $39M | · | · | · | · | |
| Net Debt Issued | · | · | $39M | · | · | · | · | |
| Stock Issued | $15M | · | · | · | · | $82M | $32M | |
| Net Stock Activity | $15M | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $4M | $40M | $900.0K | · | $77M | $30M | |
| Net Change in Cash | $-4M | $-8M | $4M | $-38M | · | $53M | $9M | |
| Taxes Paid | $15.0K | $41.0K | $44.0K | $17.0K | · | · | · | |
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · | · | · | |
| Levered FCF | $-37M | $-63M | $-41M | $-20M | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 85.9% | 84.5% | 82.5% | · | · | · | |
| Operating Margin | -59.4% | -88.1% | -85.1% | -79.9% | · | · | · | |
| Net Margin | -67.8% | -96.3% | -70.6% | -77.5% | · | · | · | |
| Pretax Margin | -67.8% | -96.2% | -70.4% | -77.4% | · | · | · | |
| EBITDA Margin | -56.1% | -86.3% | -83.8% | -78.3% | · | · | · | |
| ROA | -71.4% | -64.6% | -33.7% | -24.9% | · | · | · | |
| ROE | 328.9% | -739.5% | -63.2% | -30.9% | · | · | · | |
| ROIC | -161.5% | -121.2% | -48.1% | -32.5% | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · | · | · | |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · | · | · | |
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 9.4 | 0.8 | · | · | · | · | |
| Interest Coverage | -8.5 | -10.6 | -37.3 | -1719.1 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 0.7 | 0.5 | 0.3 | · | · | · | |
| Inventory Turnover | 1.8 | 1.4 | 2.0 | 2.8 | · | · | · | |
| Receivables Turnover | 6.9 | 6.6 | 9.0 | 10.4 | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.54 | $0.17 | $1.91 | $3.36 | · | · | · | |
| Revenue / Share | $2.57 | $2.48 | $1.98 | $1.38 | · | · | · | |
| Cash Flow / Share | $-1.12 | $-1.89 | $-1.50 | $-0.76 | · | · | · | |
| Cash / Share | $0.34 | $0.53 | $0.86 | $0.72 | · | · | · | |
| EPS (TTM) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.5% | 28.1% | 45.7% | · | · | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $64M | $50M | $34M | · | $14M | · | |
| Net Income TTM | $-49M | $-62M | $-35M | $-27M | · | $-42M | · | |
| Market Cap | $105M | $337M | $352M | $166M | · | · | · | |
| Enterprise Value | $130M | $344M | $303M | · | · | · | · | |
| P/E | -2.0 | -5.4 | -9.8 | 6.2 | · | 14.8 | · | |
| P/S | 1.5 | 5.3 | 7.0 | 4.8 | · | · | · | |
| P/B | -6.3 | 75.0 | 7.2 | 2.0 | · | · | · | |
| P / Tangible Book | · | · | 7.3 | 2.0 | · | 9.1 | · | |
| P / Cash Flow | -3.4 | -6.9 | -9.3 | -8.7 | · | · | · | |
| P / FCF | -3.3 | -5.8 | -8.9 | -8.5 | · | · | · | |
| EV / EBITDA | -3.2 | -6.2 | -7.2 | · | · | · | · | |
| EV / FCF | -4.0 | -5.9 | -7.7 | · | · | · | · | |
| EV / Revenue | 1.8 | 5.3 | 6.0 | · | · | · | · | |
| Earnings Yield | -50.4% | -18.7% | -10.2% | 16.2% | · | 6.8% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $18M | $17M | $18M | $19M | $18M | $20M | $15M | $11M | $14M | $14M | $12M | $11M | $9M | $9M | |
| Cost of Revenue | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Gross Profit | $18M | $16M | $14M | $14M | $15M | $16M | $16M | $16M | $13M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | |
| R&D Expense | $5M | $6M | $6M | $4M | $5M | $6M | $5M | $5M | $5M | $5M | $7M | $4M | $5M | $5M | $3M | $4M | |
| SG&A Expense | $6M | $6M | $7M | $7M | $7M | $6M | $7M | $10M | $8M | $9M | $8M | $6M | $6M | $8M | $5M | $5M | |
| Operating Expenses | $25M | $25M | $25M | $23M | $26M | $28M | $26M | $30M | $29M | $27M | $25M | $21M | $21M | $19M | $15M | $14M | |
| Operating Income | $-7M | $-9M | $-10M | $-9M | $-11M | $-12M | $-10M | $-14M | $-16M | $-17M | $-12M | $-9M | $-11M | $-10M | $-6M | $-6M | |
| Interest Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $10.0K | $7.0K | $4.0K | $-3.0K | $6.0K | |
| Other Non-op | $688.0K | $-395.0K | $20.0K | $-3M | $2M | $-791.0K | $-314.0K | $-1M | $2M | $-66.0K | $6M | $615.0K | $801.0K | $725.0K | · | · | |
| Pretax Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| Income Tax | $33.0K | $-11.0K | $-16.0K | $15.0K | $4.0K | $8.0K | $19.0K | $-28.0K | $33.0K | $30.0K | $12.0K | $11.0K | $13.0K | $30.0K | $24.0K | $4.0K | |
| Net Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| EPS (Basic) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| EPS (Diluted) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| Shares (Basic) | 30,749,894 | 30,540,872 | · | 28,393,445 | 26,367,548 | 26,253,565 | · | 25,983,929 | 25,760,278 | 25,637,783 | · | 25,401,754 | 25,239,723 | 25,202,088 | · | 25,006,995 | |
| Shares (Diluted) | 30,749,894 | 30,540,872 | · | 28,393,445 | 26,367,548 | 26,253,565 | · | 25,983,929 | 25,760,278 | 25,637,783 | · | 25,401,754 | 25,239,723 | 25,202,088 | · | 25,006,995 | |
| EBITDA | $-7M | $-8M | · | $-9M | $-11M | $-11M | · | $-14M | $-16M | $-17M | · | $-9M | $-11M | $-10M | · | $-6M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $8M | $10M | $15M | $12M | $15M | $14M | $19M | $17M | $17M | $22M | $51M | $37M | $28M | $18M | $24M | |
| Short-term Investments | $2M | $6M | $8M | $8M | $3M | $11M | $22M | $26M | $37M | $51M | $67M | $9M | $29M | $45M | $61M | $61M | |
| Receivables | $10M | $10M | $9M | $9M | $11M | $12M | $12M | $10M | $9M | $7M | $8M | $6M | $6M | $5M | $4M | $4M | |
| Inventory | $5M | $6M | $7M | $7M | $8M | $8M | $7M | $6M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $3M | $2M | $1M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $8.0K | $135.0K | · | $26.0K | $525.0K | $29.0K | $127.0K | $17.0K | |
| Current Assets | $28M | $32M | $35M | $41M | $36M | $48M | $57M | $64M | $73M | $86M | $104M | $74M | $77M | $83M | $87M | $92M | |
| PP&E (Net) | $8M | $8M | $9M | $10M | $10M | $10M | $10M | $9M | $7M | $4M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Intangibles | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $590.0K | $545.0K | $542.0K | $487.0K | $459.0K | $456.0K | $461.0K | $465.0K | $449.0K | |
| Other Non-current Assets | $593.0K | $534.0K | $612.0K | $1M | $839.0K | $287.0K | $546.0K | $546.0K | $473.0K | $401.0K | $355.0K | $236.0K | $285.0K | $230.0K | $122.0K | $548.0K | |
| Total Assets | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Accounts Payable | $6M | $7M | $9M | $8M | $7M | $9M | $6M | $4M | $4M | $4M | $4M | $3M | $4M | $4M | $3M | $3M | |
| Current Liabilities | $69M | $67M | $63M | $62M | $63M | $23M | $20M | $17M | $14M | $12M | $13M | $12M | $14M | $11M | $11M | $10M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | $306.0K | $405.0K | |
| Total Liabilities | $76M | $75M | $73M | $70M | $71M | $74M | $75M | $69M | $64M | $64M | $62M | $17M | $16M | $14M | $13M | $12M | |
| Long-term Debt | · | · | $43M | $42M | · | · | $42M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $47M | $46M | · | $42M | $42M | $41M | · | $43M | $41M | $41M | · | · | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $400M | $396M | $394M | $393M | $374M | $371M | $368M | $364M | $359M | $353M | $350M | $347M | $344M | $342M | $340M | $338M | |
| Retained Earnings | $-427M | $-419M | $-408M | $-397M | $-384M | $-374M | $-360M | $-348M | $-332M | $-317M | $-298M | $-291M | $-282M | $-272M | $-263M | $-257M | |
| AOCI | $-82.0K | $648.0K | $-1M | $-1M | $-2M | $-413.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $8M | $8M | $8M | $8M | $7M | |
| Stockholders' Equity | $-28M | $-23M | $-17M | $-7M | $-13M | $-5M | $4M | $12M | $24M | $33M | $49M | $63M | $69M | $78M | $85M | $88M | |
| Liabilities + Equity | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Shares Outstanding | 30,926,847 | 30,776,689 | 30,571,662 | 30,493,111 | 26,613,678 | 26,434,658 | 26,354,042 | 26,217,629 | 25,949,906 | 25,789,051 | 25,682,078 | 25,550,694 | 25,447,615 | 25,327,761 | 25,208,436 | 25,030,902 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $605.0K | $627.0K | $700.0K | $574.0K | $552.0K | $521.0K | $409.0K | $310.0K | $204.0K | $203.0K | $187.0K | $164.0K | $146.0K | $135.0K | $130.0K | $138.0K | |
| Stock-based Comp | $2M | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $2M | $2M | $1M | $3M | $1M | $1M | |
| Amort. of Intangibles | $196.0K | $204.0K | $160.0K | $153.0K | $152.0K | $135.0K | $36.0K | $23.0K | $17.0K | $17.0K | $9.0K | $9.0K | $8.0K | $9.0K | $8.0K | $8.0K | |
| Other Non-cash | · | $-1M | · | · | · | $335.0K | · | · | · | $-5M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-3M | $-10M | $-5M | $-5M | $-10M | $-10M | $-8M | $-7M | $-13M | $-21M | $-11M | $-9M | $-9M | $-9M | $-3M | $-3M | |
| CapEx | $108.0K | $19.0K | $-674.0K | $934.0K | $524.0K | $221.0K | $2M | $4M | $3M | $1M | $296.0K | $502.0K | $299.0K | $284.0K | $70.0K | $104.0K | |
| Investing Cash Flow | $4M | $2M | $11.0K | $-5M | $7M | $11M | $2M | $7M | $12M | $15M | $-57M | $22M | $18M | $19M | $-3M | $-8M | |
| Stock Issued | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $437.0K | $6M | $248.0K | $14M | $559.0K | $363.0K | $1M | $1M | $849.0K | $631.0K | $39M | $600.0K | $171.0K | $171.0K | $899.0K | $0 | |
| Net Change in Cash | $830.0K | $-2M | $-5M | $3M | $-3M | $820.0K | $-5M | $1M | $501.0K | $-5M | $-29M | $13M | $9M | $10M | $-6M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | $20.0K | $2.0K | $19.0K | $17.0K | $0 | $0 | $44.0K | $9 | $0 | $0 | |
| Free Cash Flow | · | $-10M | · | · | · | $-11M | · | · | · | $-22M | · | · | · | $-9M | · | · | |
| Levered FCF | · | $-12M | · | · | · | $-12M | · | · | · | $-23M | · | · | · | $-9M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.7% | · | 81.3% | 81.2% | 84.7% | · | 83.7% | 86.1% | 86.4% | · | 84.5% | 81.2% | 84.2% | · | 83.2% | |
| Operating Margin | -31.6% | -45.7% | · | -53.6% | -60.5% | -63.9% | · | -70.6% | -102.8% | -155.0% | · | -68.2% | -95.0% | -93.9% | · | -63.2% | |
| Net Margin | -35.3% | -55.1% | · | -77.3% | -53.9% | -74.9% | · | -82.9% | -101.3% | -168.0% | · | -63.8% | -88.3% | -87.4% | · | -61.5% | |
| Pretax Margin | -35.2% | -55.2% | · | -77.2% | -53.8% | -74.8% | · | -83.0% | -101.1% | -167.8% | · | -63.8% | -88.2% | -87.1% | · | -61.4% | |
| EBITDA Margin | -31.6% | -42.5% | · | -53.6% | -60.5% | -61.1% | · | -70.6% | -102.8% | -153.1% | · | -68.2% | -95.0% | -92.7% | · | -63.2% | |
| ROA | -14.5% | -17.5% | · | -18.2% | -13.6% | -16.6% | · | -20.0% | -17.7% | -19.6% | · | -9.6% | -11.0% | -9.3% | · | -4.9% | |
| ROE | 37.6% | 76.5% | · | -474.3% | -180.0% | -99.0% | · | -43.1% | -33.3% | -33.9% | · | -11.5% | -12.9% | -10.5% | · | -5.4% | |
| ROIC | -36.6% | -38.3% | · | -25.6% | -38.0% | -32.1% | · | -25.2% | -24.1% | -23.3% | · | -14.8% | -16.3% | -12.8% | · | -6.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.5 | · | 0.7 | 0.6 | 2.1 | · | 3.7 | 5.3 | 7.2 | · | 6.2 | 5.6 | 7.2 | · | 9.6 | |
| Quick Ratio | 0.3 | 0.4 | · | 0.5 | 0.4 | 1.6 | · | 3.2 | 4.6 | 6.3 | · | 5.6 | 5.2 | 6.8 | · | 9.2 | |
| Debt / Equity | -1.7 | -2.0 | · | -6.4 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.0 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Interest Coverage | -4.7 | -6.2 | · | -7.2 | -8.9 | -9.6 | · | -10.2 | -11.6 | -12.7 | · | -930.6 | -1595.0 | -2477.8 | · | -958.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.9 | 0.7 | · | 0.8 | |
| Receivables Turnover | 2.0 | 1.8 | · | 1.8 | 1.8 | 1.9 | · | 2.4 | 2.1 | 1.9 | · | 2.9 | 2.4 | 2.6 | · | 3.1 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.90 | $-0.75 | · | $-0.22 | $-0.48 | $-0.17 | · | $0.47 | $0.92 | $1.26 | · | $2.46 | $2.70 | $3.06 | · | $3.52 | |
| Revenue / Share | $0.71 | $0.63 | · | $0.60 | $0.70 | $0.71 | · | $0.75 | $0.59 | $0.43 | · | $0.54 | $0.47 | $0.42 | · | $0.36 | |
| Cash Flow / Share | · | $-0.33 | · | · | · | $-0.39 | · | · | · | $-0.81 | · | · | · | $-0.36 | · | · | |
| Cash / Share | $0.30 | $0.27 | · | $0.51 | $0.46 | $0.56 | · | $0.71 | $0.67 | $0.66 | · | $1.99 | $1.47 | $1.11 | · | $0.94 | |
| EPS (TTM) | $-1.43 | $-1.56 | · | $-1.81 | $-1.97 | $-2.19 | · | $-2.23 | $-1.95 | $-1.76 | · | $-0.90 | $-0.34 | $0.32 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $76M | $72M | · | $72M | $75M | $72M | · | $60M | $54M | $51M | · | $45M | $41M | $37M | · | · | |
| Net Income TTM | $-43M | $-45M | · | $-49M | $-52M | $-57M | · | $-57M | $-50M | $-45M | · | $-34M | $-31M | $-26M | · | · | |
| Market Cap | $128M | $114M | · | $156M | $141M | $215M | · | $281M | $206M | $413M | · | $373M | $433M | $354M | · | $132M | |
| Enterprise Value | $163M | $146M | · | $175M | $167M | $231M | · | $279M | $192M | $387M | · | · | · | · | · | · | |
| P/E | -2.9 | -2.4 | · | -2.8 | -2.7 | -3.7 | · | -4.8 | -4.1 | -9.1 | · | -16.2 | -50.0 | 43.7 | · | · | |
| P/S | 1.7 | 1.6 | · | 2.2 | 1.9 | 3.0 | · | 4.7 | 3.8 | 8.2 | · | 8.2 | 10.6 | 9.5 | · | · | |
| P/B | -4.6 | -4.9 | · | -23.4 | -10.9 | -47.1 | · | 23.0 | 8.6 | 12.7 | · | 5.9 | 6.3 | 4.6 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | 24.2 | 8.8 | 12.9 | · | 6.0 | 6.3 | 4.6 | · | 1.5 | |
| P / Cash Flow | · | -11.3 | · | · | · | -20.9 | · | · | · | -19.8 | · | · | · | -39.0 | · | · | |
| EV / Revenue | 2.2 | 2.0 | · | 2.4 | 2.2 | 3.2 | · | 4.7 | 3.6 | 7.6 | · | · | · | · | · | · | |
| Earnings Yield | -34.6% | -42.2% | · | -35.4% | -37.2% | -26.9% | · | -20.8% | -24.6% | -11.0% | · | -6.2% | -2.0% | 2.3% | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · |
| Gross Margin % | 82.1% | 85.9% | 84.5% | 82.5% | · |
| Operating Margin % | -59.4% | -88.1% | -85.1% | -79.9% | · |
| Net Income | $-49M | $-62M | $-35M | $-27M | · |
| Diluted EPS | $-1.74 | $-2.39 | $-1.40 | $1.07 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · |
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · |
Institutional owners (13F) 80 filers · $25.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 23 (-6 vs prior Q) | 24 (+11 vs prior Q) | 25 (-4 vs prior Q) | 21 (+11 vs prior Q) | -82.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5,509,065 | 1,333,914 | 21.63% | Shares |
| VANGUARD GROUP INC | $4,983,797 | 1,444,579 | 19.57% | Shares |
| BlackRock, Inc. | $2,333,251 | 564,952 | 9.16% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,404,076 | 339,822 | 5.51% | Shares |
| MARSHALL WACE, LLP | $1,397,539 | 338,387 | 5.49% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $1,325,784 | 321,013 | 5.21% | Shares |
| MORGAN STANLEY | $827,909 | 200,462 | 3.25% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $753,320 | 182,402 | 2.96% | Shares |
| NewEdge Advisors, LLC | $615,085 | 148,931 | 2.42% | Shares |
| MACQUARIE GROUP LTD | $595,395 | 144,164 | 2.34% | Shares |
| STATE STREET CORP | $532,675 | 128,977 | 2.09% | Shares |
| Quantinno Capital Management LP | $434,674 | 105,248 | 1.71% | Shares |
| Divisadero Street Capital Management, LP | $413,000 | 100,000 | 1.62% | Shares |
| UBS Group AG | $347,056 | 84,033 | 1.36% | Shares |
| GOLDMAN SACHS GROUP INC | $316,924 | 76,737 | 1.24% | Shares |
| NORTHERN TRUST CORP | $284,858 | 68,973 | 1.12% | Shares |
| Qube Research & Technologies Ltd | $263,428 | 63,784 | 1.03% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $250,881 | 60,746 | 0.99% | Shares |
| XTX Topco Ltd | $236,075 | 57,161 | 0.93% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $222,847 | 53,958 | 0.87% | Shares |
| BANK OF AMERICA CORP /DE/ | $213,384 | 51,667 | 0.84% | Shares |
| FMR LLC | $134,287 | 32,515 | 0.53% | Shares |
| IEQ CAPITAL, LLC | $133,812 | 32,400 | 0.53% | Shares |
| THOMPSON DAVIS & CO., INC. | $128,402 | 31,090 | 0.50% | Shares |
| Jain Global LLC | $127,101 | 30,775 | 0.50% | Shares |
| AMERIPRISE FINANCIAL INC | $119,823 | 29,013 | 0.47% | Shares |
| Russell Investments Group, Ltd. | $115,863 | 28,054 | 0.45% | Shares |
| IHT Wealth Management, LLC | $101,599 | 24,600 | 0.40% | Shares |
| Squarepoint Ops LLC | $95,035 | 23,011 | 0.37% | Shares |
| R Squared Ltd | $94,506 | 22,883 | 0.37% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92,512 | 22,400 | 0.36% | Call option |
| CITADEL ADVISORS LLC | $87,746 | 21,246 | 0.34% | Shares |
| Mariner, LLC | $81,090 | 19,634 | 0.32% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65,254 | 15,800 | 0.26% | Put option |
| CITADEL ADVISORS LLC | $65,254 | 15,800 | 0.26% | Put option |
| Abel Hall, LLC | $65,167 | 15,779 | 0.26% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64,734 | 15,674 | 0.25% | Shares |
| MILLENNIUM MANAGEMENT LLC | $63,722 | 15,429 | 0.25% | Shares |
| GABELLI FUNDS LLC | $61,950 | 15,000 | 0.24% | Shares |
| nVerses Capital, LLC | $56,448 | 13,668 | 0.22% | Shares |
| Cerity Partners LLC | $53,100 | 12,857 | 0.21% | Shares |
| China Universal Asset Management Co., Ltd. | $51,625 | 12,500 | 0.20% | Shares |
| Quadrature Capital Ltd | $48,854 | 11,829 | 0.19% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $48,073 | 11,640 | 0.19% | Shares |
| Vanguard Global Advisers, LLC | $40,201 | 9,734 | 0.16% | Shares |
| AlphaQuest LLC | $32,354 | 9,378 | 0.13% | Shares |
| Arax Advisory Partners | $29,542 | 7,153 | 0.12% | Shares |
| ROYAL BANK OF CANADA | $29,000 | 7,084 | 0.11% | Shares |
| RHUMBLINE ADVISERS | $27,302 | 6,611 | 0.11% | Shares |
| CWM, LLC | $19,632 | 5,306 | 0.08% | Shares |
Company insiders 20 insiders · 11 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Cary Guy Vance | President and CEO | May 29, 2026 A | 40,771 | 0 | 0 | $0 |
| James Corbett | CEO | Jan. 21, 2025 A | 11,580 | 0 | 0 | $0 |
| David D O'Toole | CFO | June 12, 2026 P | 152,927 | 5 | 0 | $45,994 |
| Sean Ekins | Interim CFO | June 6, 2023 A | 5,000 | 0 | 0 | $0 |
| Michael Holder | Chief Financial Officer | July 1, 2022 A | 46,450 | 0 | 0 | $0 |
| David Mcintyre | Chief Financial Officer | July 17, 2020 P | 893 | 0 | 0 | $0 |
| Kathy M. Mcgee | Chief Operating Officer | July 1, 2022 A | 46,450 | 0 | 0 | $0 |
| Nicole Kelsey | Chief Legal Officer | Feb. 18, 2026 A | 98,390 | 0 | 0 | $0 |
| Donna Shiroma | General Counsel | May 31, 2024 A | 45,951 | 0 | 0 | $0 |
| Andrew Quick | Chief Technology Officer | June 6, 2023 A | 46,450 | 0 | 0 | $0 |
| Erin Liberto | Chief Commercial Officer | July 1, 2022 A | 46,450 | 0 | 0 | $0 |
| Joseph Fralin Woody | Director | June 9, 2026 P | 107,961 | 9 | 0 | $188,600 |
| Suzanne Crowe | Director | Jan. 20, 2026 A | 69,148 | 0 | 0 | $0 |
| Michael E Tarnoff | Director | Jan. 20, 2026 A | 48,464 | 0 | 0 | $0 |
| Robert Mcnamara | Director | Jan. 20, 2026 A | 108,985 | 0 | 0 | $0 |
| Jeremy Curnock Cook | Director | Jan. 20, 2026 A | 62,050 | 0 | 0 | $0 |
| Jan Stern Reed | Director | Jan. 20, 2026 A | 73,225 | 0 | 0 | $0 |
| Lou Panaccio | Director | Jan. 21, 2025 A | 56,428 | 0 | 0 | $0 |
| Michael S Perry | Director | Nov. 21, 2022 M | 229,543 | 0 | 0 | $0 |
| Louis Drapeau | Director | Dec. 22, 2021 A | 4,689 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
RCEL Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
3 analysts · 2026-10-01Mean target $12.00 -5.6%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| SPRY | $1.16B | -6.7 | -5.5% | -203.3% | -111.8% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| EIKN | · | · | · | · | · | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| KYTX | $568M | -2.6 | · | · | -77.4% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.